Ivory Coast launches Ebola vaccination, is monitoring 9 contacts

The Ivory Coast yesterday launched an Ebola vaccination campaign aimed at frontline health workers and other high-risk groups, part of the response into an imported Ebola case involving a woman who had just arrived from Guinea.

In a statement today, the World Health Organization (WHO) African regional office said following the confirmation of the initial case, investigators have identified one suspected case and nine contacts who are being monitored.

The country is using Merck's VSV-EBOV vaccine for the vaccine campaign, using supplies quickly sent from Guinea to Ivory Coast. The 2,000 doses will be used in a ring vaccination strategy, as well as to immunize healthcare workers. Guinea also sent 3,000 doses of the Johnson & Johnson Ebola vaccine, which it will use in areas that aren't experiencing active transmission.

In addition, Guinea deployed five vaccination experts and made monoclonal antibody treatments available. The patient, an 18-year-old woman who had traveled from Labe in northwestern Guinea to the major urban center of Abidjan in Ivory Coast last week is receiving treatment at a hospital in Abidjan.

The patient's infection does not appear to be linked to Guinea's earlier outbreak, which was declared over in the middle of June. The woman's Ebola infection is the Ivory Coast's first since 1994.
Aug 17 WHO African regional office statement

 

Indian report notes gaps in guidance on antibiotic use in food animals

A new report by an Indian public interest research and advocacy organization highlights gaps in global recommendations on antibiotic use in food-producing animals and calls for more uniform guidance from the Tripartite United Nations (UN) organizations.

The report from the Centre for Science and Environment notes that while the WHO, the UN Food and Agriculture Organization (FAO), and the World Organization for Animal Health (OIE) all have their own guidance on the use of antibiotics in food-producing animals, there is significant overlap in the antibiotics considered critical for human medicine and veterinary medicine. For example, 47 of the antimicrobials listed by the OIE as being important for veterinary medicine are also on the WHO's list of critically important antibiotics for human medicine.

The report also points out a lack of coherence among the organizations on how antibiotics should be used in food-producing animals. Although there is uniform agreement that critically important antibiotics for human medicine should not be used for growth promotion in livestock, there is less agreement on whether they should be used for disease prevention and control in herds and flocks, or whether critically important antibiotics should be used to treat sick animals.

"Clearly, there is need for more clarity, coherence and, most importantly, a uniform message from the Tripartite organizations," the authors write. "In the absence of this, chances of consensus among national-level animal- and human-health stakeholders are low and the possibility for misinterpretation remains high. This can result in limited action, leading to misuse and overuse of critically important antimicrobials in the food-producing animal sector."

The authors say the organizations should develop uniform guidance that contains a clear message about which critically important antibiotics can be used across the food-animal sector, how they should be used, and which should be prohibited immediately or phased out. They also call for the Tripartite organizations to develop a better understanding of how countries are using critically important antibiotics in food-producing animals, and the levels of resistance to those antibiotics.

The report also contains recommendations for the Indian government to develop a roadmap and policy framework for conserving the use of these antibiotics in the food-animal sector.
Aug 16 Centre for Science and Environment report

 

CDC: More Salmonella illnesses linked to frozen shrimp

Yesterday the Centers for Disease Control and Prevention (CDC) announced three new cases of Salmonella Weltevreden illnesses linked to frozen cooked shrimp in a multistate outbreak, raising the number of confirmed cases to nine. Two more states are affected, and the recall of shrimp products has been expanded.

Three people have required hospitalization, but no deaths have been reported in this outbreak. Cases have been detected in Nevada (4 cases), Arizona (2), Michigan (2), and Rhode Island (1). At least five of the patients report eating shrimp in the week prior to symptom onset. Illness-onset dates range from Feb 26 to Jul 17. Patients range in age from 30 to 80, with a median of 60.

The outbreak was detected by the Food and Drug Administration (FDA) when a sample of Avanti Frozen Foods shrimp that was collected for testing at import was found to be contaminated with Salmonella Weltevreden.

The CDC said the shrimp in question were sold under multiple brands and distributed from November 2020 to May 2021.

"On August 13, 2021, Avanti Frozen Foods expanded their initial recall to include additional brands and expiration dates," the agency wrote. "CDC urges consumers and retailers with frozen cooked shrimp in their freezers to carefully review the product tables in both recall notices and throw away or return any recalled products."
Aug 16 CDC
update
Aug 13 FDA notice of expanded
recall

 

WHO details India's first H5N1 avian flu case, fatal with flu B coinfection

The WHO yesterday fleshed out more details about a human H5N1  avian flu case recently reported by the media. The patient is a boy younger than 18 years old from Haryana state in the north who had been receiving immunosuppressive therapy for an underlying health condition before he got sick.

His symptoms began on Jun 12, and his condition worsened, requiring mechanical ventilation. He died on Jul 12.

Respiratory samples collected on two dates in July while he was sick were positive for influenza A and influenza B. After he died, the samples were sent to the country's National Institute of Virology for further testing, which revealed H5N1 and influenza B (Victoria lineage). Whole-genome sequencing and virus isolation are under way.

The investigation revealed that, over the past year, the boy lived with a family member who owns a butchery, but no reports of poultry illnesses or deaths had been reported in the area. So far, the source of the infection isn't known, and none of the boy's family members have shown similar symptoms.

The WHO said the risk of human-to-human infection appears low, but sporadic H5 infections may be reported in India because of occasional detections in poultry. India has reported H5N1 on poultry farms every year since 2016, and earlier this year, Haryana state reported H5N8 outbreaks in poultry.
Aug 16 WHO statement

COVID-19 Scan for Aug 17, 2021

News brief

China's COVID-19 vaccine tied to slight risk of Bell's palsy

China's CoronaVac COVID-19 vaccine is tied to a slight increased risk of Bell's palsy, while the Fosun/BioNTech (Pfizer/BioNTech's parallel product in China) did not show a significantly increased risk, according to a study yesterday in The Lancet Infectious Diseases. Both the researchers and a related commentary conclude that COVID-19 vaccines' benefits outweigh the risks.

Bell's palsy mainly manifests as one-sided facial paralysis and resolves itself 70% of the time—90% of the time if the patient receives early treatment with corticosteroids.

The researchers looked at Hong Kong residents who were vaccinated with either COVID-19 vaccine from Feb 23 to May 4, first using population-based data to determine prevalence and then using a case-control study to tease out odds ratios. Out of 451,939 adults who received at least the first dose of CoronaVac, there were 28 clinically confirmed cases of Bell's palsy, or 3.61 cases per 100,000 vaccinated people. For Fosun/BioNTech, 16 cases were identified among 537,205 recipients, or 2.04 people per 100,000.

The nested case-control study matched Bell's palsy patients with other emergency department or hospital patients 1:4. Data indicated that the CoronaVac vaccine was associated with a 2.4-fold increased risk of Bell's palsy (95% confidence interval [CI], 1.4 to 4.0), and the Fosun/BioNTech vaccine was tied with a 1.8-fold increased risk that was not statistically significant (95% CI, 0.9 to 3.5). The researchers note that the data for the Fosun/BioNTech vaccine may be underpowered.

"From a clinical, patient-oriented perspective, none of the studies published so far provide definitive evidence to inform the choice of a specific vaccine in individuals worldwide with a history of Bell's palsy," write Nicola Cirillo, DMD, PhD, and Richard Doan, MD, in a related commentary.

"However, the data published by Wan and colleagues do offer valuable information for a rational and informed choice of COVID-19 vaccines for patients in Hong Kong, and for those in countries where both BNT162b2 and CoronaVac are available. While waiting for conclusive evidence on vaccine-associated facial paralysis, one certainty remains: The benefit of getting vaccinated outweighs any possible risk."
Aug 16 Lancet Infect Dis study and commentary

 

COVID vaccine well-tolerated in pregnancy, lactation, study says

Most pregnant and lactating people had at least one short-term reaction after receiving COVID-19 vaccines but tolerated them well overall, according to a research letter today in JAMA Network Open.

The researchers analyzed data on 17,525 primarily US adults (mean age, 33.6 years; 87.6% White) who were pregnant (44.6%), lactating (38.7%), or neither but planning to be pregnant in the near future (16.5%) who had just gotten their first dose of the COVID-19 vaccine by Mar 16. Most were employed in healthcare, and of the 17,431 with known vaccination types, 61.9% received Pfizer/BioNTech while 38.7% received Moderna.

Almost all (97.0%) had some sort of reaction after the first dose, most commonly injection-site pain (91.4%) or fatigue (31.3%), and even more had reactions after the second dose.

Obstetric-related reactions were reported in 4.4% after the first dose and 7.5% after the second dose. Pregnant people were statistically less likely to have certain reactions (eg, fever after a second Pfizer/BioNTech or Moderna dose; odds ratio, 0.44 to 0.48) compared with those who were not pregnant nor lactating. Interrupted breastfeeding occurred in 2.3% of lactating recipients after the first dose and 2.2% after the second, while decreased milk supply for less than 24 hours occurred in 5.0% after the first dose and 7.2% after the second dose.

Overall, 84.3% of pregnant vaccine recipients had a second dose by the time of data analysis, of whom 4.3% had delivered their baby and 0.7% had a miscarriage.

"This large prospective cohort study found that COVID-19 vaccines were well-tolerated among individuals who were pregnant, lactating, or planning pregnancy," the researchers conclude.
Aug 17 JAMA Netw Open study

This week's top reads

Our underwriters